Shannon Thyme Klinger sold $486k of MRNA
Chief Legal Officer at Moderna, Inc.. 3,471 shares at an average of $139.95, traded Sep 1, 2026, filed Sep 3, 2026.
Score components
- +15RoleOfficer
- +18Trade size$486k at market
- 0Share of holdings soldSold 4.5% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001682852-26-000167, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | MOption exercise Common Stock10b5-1 | +3,471 | $30.96 | $107k | 77,600 | 39 d ago |
| Sep 1, 2026 | SOpen-market sale Common Stock10b5-1 | -3,471 | $139.95 | $486k | 74,129 | 39 d ago |
| Sep 1, 2026 | MOption exercise Common Stock10b5-1 | +2,166 | - | - | 76,295 | 39 d ago |
| Sep 1, 2026 | FTax withholding Common Stock10b5-1 | -1,048 | $140.34 | $147k | 75,247 | 39 d ago |
| Sep 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,471 | $0.00 | $0 | 34,716 | 39 d ago |
| Sep 1, 2026 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -2,166 | $0.00 | $0 | 21,661 | 39 d ago |
Related signals
Other insiders at Moderna, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Moderna, Inc. | Stephen Hoge President | $12M 80,575 shares | -5% | |
| 37Weak | Moderna, Inc. | James M Mock Chief Financial Officer | $4.7M 34,836 shares | -37% | |
| 5Weak | Moderna, Inc. | Abbas Hussain director | $8,736 312 shares | -35% | |
| 50Moderate | MRNAbuy Moderna, Inc. | Stephane Bancel Chief Executive Officer | $5.0M 160,314 shares | +2% | |
| 0Weak | Moderna, Inc. | Shannon Thyme Klinger Chief Legal Officer | $24k 529 shares | -3% | |
| 0Weak | Moderna, Inc. | Stephen Hoge President | $14k 314 shares | -0% | |
| 0Weak | Moderna, Inc. | Shannon Thyme Klinger Chief Legal Officer | $4,849 112 shares | -1% | |
| 0Weak | Moderna, Inc. | Stephen Hoge President | $12k 291 shares | -0% | |
| 2Weak | Moderna, Inc. | Shannon Thyme Klinger Chief Legal Officer | $61k 1,418 shares | -7% | |
| 14Weak | Moderna, Inc. | James M Mock Chief Financial Officer | $61k 1,420 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.